共 43 条
- [22] Fecal Microbiota, Live-js']jslm (RBL; REBYOTA™) for Recurrent Clostridioides difficile Infection JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2024, 20 (10):
- [23] Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity EBIOMEDICINE, 2016, 13 : 37 - 45
- [25] Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US Advances in Therapy, 2023, 40 : 2801 - 2819
- [26] Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis Infectious Diseases and Therapy, 2021, 10 : 201 - 211
- [27] Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-js']jslm (REBYOTA™) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
- [30] Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA Advances in Therapy, 2023, 40 : 2784 - 2800